Urea for Treatment of SIAD Induced Hyponatremia: Experience of an Oncology Center
Authors' conclusion
Our study suggests that urea may be a safe, effective, and well-tolerated option for the long-term management of SIAD-related hyponatremia in oncology patients, but further studies are necessary to confirm these observations.
Study context
- Population
- Patients with cancer and chronic SIAD-induced hyponatremia treated with oral urea at an Oncology Center, August 2021–June 2023; 71% men, mean age 63.9 ± 10.0 years, 86% metastatic disease; lung cancer most frequent
- Participants
- 28 patients
- Exposure
- Inpatients vs Outpatients
- Outcome
- Serum sodium change with urea (efficacy and safety)
- Follow-up
- First reevaluation and last available
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Serum sodium increase
| Group | Value | Time to reevaluation | p |
|---|---|---|---|
| Inpatients | mean 2.4 ± 3.5 mmol/L | 12 (23) hours | p = 0.016 |
| Outpatients | mean 8.6 ± 6.6 mmol/L | 8 (11) days | p = 0.003 |
Value
Inpatientsmean 2.4 ± 3.5 mmol/L
Outpatientsmean 8.6 ± 6.6 mmol/L
Time to reevaluation
Inpatients12 (23) hours
Outpatients8 (11) days
p
Inpatientsp = 0.016
Outpatientsp = 0.003
Observational data: associations, not effects.
Further findings
Urea discontinuation after sodium normalization following cancer treatment · median follow-up 84 days (range 3 days-20.9 months)
- Urea discontinued
- 21%
Safety
- Sodium overcorrection
- 0
- Clinically significant adverse events
- 0
- Complained of urea taste, no impact on adherence
- 1 patient
Original publication
Urea for Treatment of SIAD Induced Hyponatremia: Experience of an Oncology Center. Clin Endocrinol (Oxf). Published 24 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →